Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITHIODOTE vs MAYZENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.
Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.
FDA-approved for the treatment of acute cyanide poisoning,Off-label: May be used for cyanide poisoning due to smoke inhalation or certain chemical exposures
Relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.
0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.
Terminal elimination half-life: 2.5–3 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 8–10 days due to slow dissociation from sphingosine 1-phosphate receptors; steady-state reached in 3–4 weeks.
Sodium nitrite is partially metabolized to nitric oxide and other metabolites; sodium thiosulfate is primarily excreted unchanged in urine, with minor metabolism by rhodanese in the liver and kidneys.
Primarily metabolized by CYP3A4 and to a minor extent by CYP2C8; also undergoes reversible phosphorylation to active metabolite.
Primarily renal as unchanged drug and metabolites; biliary/fecal excretion minimal (<5%).
Primarily fecal (≈76% as metabolites) and renal (≈24% as metabolites and minor unchanged drug).
Approximately 90% bound to albumin.
>99.9% bound to plasma proteins, primarily albumin and lipoproteins.
0.35 L/kg, indicating moderate tissue distribution.
Very large, approximately 3000 L (≈43 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Oral: 60–80% (first-pass metabolism); IV: 100%.
Oral bioavailability is approximately 84% (absolute); food does not significantly affect absorption.
No dose adjustment required for mild-moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), consider reducing sodium thiosulfate dose by 50% and monitoring serum thiocyanate levels.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Severe renal impairment (GFR <30 m L/min): not recommended due to limited data.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate-severe (Child-Pugh B/C), use with caution; consider reducing sodium nitrite dose by 50% due to increased methemoglobinemia risk.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). Mild to moderate hepatic impairment (Child-Pugh class A or B): no dose adjustment needed.
Children: Sodium nitrite 0.15-0.33 m L/kg of 3% solution (4.5-10 mg/kg) IV push over 2 minutes, followed by sodium thiosulfate 1.65 m L/kg of 25% solution (412.5 mg/kg) IV push over 10 minutes. Repeat half doses if symptoms persist.
Not approved for use in pediatric patients; safety and efficacy not established.
Geriatric patients: Use weight-based dosing (same as adult). Start with lower doses (e.g., sodium nitrite 5 mg/kg) due to increased risk of hypotension and methemoglobinemia. Monitor vital signs frequently.
No specific dose adjustment recommended; use with caution due to increased risk of infections and arrhythmias.
None
Increased risk of infections due to dose-dependent reduction in peripheral lymphocyte count; live attenuated vaccines should be avoided during and for 4 weeks after treatment.
May cause severe hypotension, especially in children,Risk of methemoglobinemia with excessive sodium nitrite,Use caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as hemolysis may occur,Monitor methemoglobin levels, blood pressure, and oxygen saturation during therapy,Sodium thiosulfate may cause hypocalcemia in high doses
Increased risk of infections,Cardiovascular effects (bradyarrhythmia, AV block, QT prolongation),Respiratory effects (decline in pulmonary function),Hepatic injury,Fetal risk (teratogenicity),Macular edema,Posterior reversible encephalopathy syndrome (PRES),Increased risk of skin malignancies,Hypertension
Hypersensitivity to any component of the product,Children under 6 months of age (relative contraindication due to increased risk of hypotension and methemoglobinemia)
Recent myocardial infarction, unstable angina, stroke/TIA, decompensated heart failure, or Mobitz type II second- or third-degree AV block in patients not paced,Severe active infections,Active malignancies except basal cell carcinoma
No known food interactions. Avoid alcohol as it may impair liver function and worsen acidosis.
Grapefruit juice may increase siponimod exposure; avoid concurrent consumption. No other significant food interactions reported; administer with or without food.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemoglobinemia and hemolytic anemia due to methylene blue component; avoid near term due to risk of neonatal methemoglobinemia.
Based on animal studies, Mayzent (siponimod) is associated with fetal harm. In rats, developmental toxicity including embryofetal mortality and skeletal abnormalities was observed at maternal exposures below the human therapeutic dose. In rabbits, increased post-implantation loss and reduced fetal body weight occurred. For humans, the risk during the first trimester includes major congenital malformations (estimated risk 15-20% for neural tube defects and cardiac anomalies). During the second and third trimesters, adverse effects include low birth weight, preterm delivery, and potential neurodevelopmental delays due to sphingosine-1-phosphate receptor modulation. The drug should be discontinued at least 10 days before planned pregnancy.
No human data; methylene blue is excreted in breast milk with an M/P ratio of approximately 0.7. Potential for infant methemoglobinemia; caution advised. Consider withholding breastfeeding for 4-6 hours after maternal dose.
Siponimod is excreted in animal milk; human data are absent. No M/P ratio is available. Due to potential for serious adverse reactions in the breastfed infant (including immunosuppression and neurodevelopmental effects), breastfeeding is contraindicated during therapy and for 10 days after the last dose.
Standard dosing (1 mg/kg IV) used in pregnancy; consider lower dose (0.5-1 mg/kg) if severe anemia or G6PD deficiency. No routine dose adjustment, but monitor for maternal hypotension and fetal bradycardia.
Pregnancy causes increased volume of distribution, enhanced CYP3A4 activity, and potential changes in protein binding that may affect siponimod pharmacokinetics. Although no specific dose adjustment studies have been conducted in pregnant women, the drug is contraindicated in pregnancy; therefore, no dose adjustments are recommended. The drug should be discontinued at least 10 days before a planned pregnancy or immediately upon discovery of pregnancy.
NITHIODOTE (sodium nitrite and sodium thiosulfate) is indicated for acute cyanide poisoning. Administer intravenously as soon as possible after exposure. Monitor methemoglobin levels; do not exceed 20% methemoglobinemia. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Sodium nitrite induces methemoglobinemia which can impair oxygen delivery; ensure adequate ventilation. Sodium thiosulfate is generally safer and can be given separately.
Initiate titration pack to minimize cardiac effects; obtain baseline ECG, LFTs, and ophthalmic exam. Monitor for bradycardia, AV block, macular edema, and infections. Avoid live vaccines. Check CYP2C9 genotype before dosing.
This medication is only used in hospital settings for cyanide poisoning.,It is given through an IV line as soon as possible after exposure.,You may experience symptoms of low oxygen such as headache, confusion, or blue skin due to methemoglobin formation.,Tell your doctor if you have a history of G6PD deficiency, anemia, or breathing problems.,Follow-up blood tests will be needed to monitor your oxygen levels and blood counts.
Do not stop taking MAYZENT without consulting your doctor, as severe disease worsening can occur.,Report any signs of infection, vision changes, or slow/irregular heartbeat immediately.,Use effective contraception during treatment and for 3 months after stopping due to potential fetal harm.,Avoid grapefruit juice, as it may increase drug levels and side effects.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITHIODOTE vs MAYZENT, answered by our medical review team.
NITHIODOTE is a Cyanide Antidote that works by Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.. MAYZENT is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITHIODOTE and MAYZENT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITHIODOTE is: NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.. The standard adult dose of MAYZENT is: 0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITHIODOTE and MAYZENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITHIODOTE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemogl. MAYZENT is classified as Category C. Based on animal studies, Mayzent (siponimod) is associated with fetal harm. In rats, developmental toxicity including embryofetal mortality and skeletal abnormalities was observed . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.